43 related articles for article (PubMed ID: 30747223)
1. Sorafenib/MEK inhibitor combination inhibits tumor growth and the Wnt/β‑catenin pathway in xenograft models of hepatocellular carcinoma.
Huynh H; Ong R; Goh KY; Lee LY; Puehler F; Scholz A; Politz O; Mumberg D; Ziegelbauer K
Int J Oncol; 2019 Mar; 54(3):1123-1133. PubMed ID: 30747223
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
Wang F; Bank T; Malnassy G; Arteaga M; Shang N; Dalheim A; Ding X; Cotler SJ; Denning MF; Nishimura MI; Breslin P; Qiu W
Hepatol Commun; 2018 Jun; 2(6):732-746. PubMed ID: 29881824
[TBL] [Abstract][Full Text] [Related]
3. Novel STAT3 oligonucleotide compounds suppress tumor growth and overcome the acquired resistance to sorafenib in hepatocellular carcinoma.
Zhang QY; Ding W; Mo JS; Ou-Yang SM; Lin ZY; Peng KR; Liu GP; Lu JJ; Yue PB; Lei JP; Wang YD; Zhang XL
Acta Pharmacol Sin; 2024 Apr; ():. PubMed ID: 38609562
[TBL] [Abstract][Full Text] [Related]
4. Activation of FcRn Mediates a Primary Resistance Response to Sorafenib in Hepatocellular Carcinoma by Single-Cell RNA Sequencing.
Guan X; Wu Y; Zhang S; Liu Z; Fan Q; Fang S; Qiao S; Sun F; Liang C
Front Pharmacol; 2021; 12():709343. PubMed ID: 34421602
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of unresectable hepatocellular carcinoma: Going beyond sorafenib.
Porta C; Paglino C
World J Hepatol; 2010 Mar; 2(3):103-13. PubMed ID: 21160981
[TBL] [Abstract][Full Text] [Related]
6. [Retracted] LINC01094 promotes the invasion of ovarian cancer cells and regulates the Wnt/β‑catenin signaling pathway by targeting miR‑532‑3p.
Chen H; Liu Y; Liu P; Dai Q; Wang P
Exp Ther Med; 2024 Jun; 27(6):257. PubMed ID: 38766308
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib kills liver cancer cells by disrupting SCD1-mediated synthesis of monounsaturated fatty acids
Liu G; Kuang S; Cao R; Wang J; Peng Q; Sun C
FASEB J; 2019 Sep; 33(9):10089-10103. PubMed ID: 31199678
[TBL] [Abstract][Full Text] [Related]
8. N
Xu J; Wan Z; Tang M; Lin Z; Jiang S; Ji L; Gorshkov K; Mao Q; Xia S; Cen D; Zheng J; Liang X; Cai X
Mol Cancer; 2020 Nov; 19(1):163. PubMed ID: 33222692
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of Transcriptional Repressor Capicua Confers Sorafenib Resistance in Human Hepatocellular Carcinoma.
Hashiba T; Yamashita T; Okada H; Nio K; Hayashi T; Asahina Y; Hayashi T; Terashima T; Iida N; Takatori H; Shimakami T; Kawaguchi K; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Takamura H; Ohta T; Honda M; Kaneko S
Cell Mol Gastroenterol Hepatol; 2020; 10(2):269-285. PubMed ID: 32169577
[TBL] [Abstract][Full Text] [Related]
10. Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment.
Wang Q; Cheng N; Wang W; Bao Y
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730647
[TBL] [Abstract][Full Text] [Related]
11. A novel diagnostic four-gene signature for hepatocellular carcinoma based on artificial neural network: Development, validation, and drug screening.
Chen M; Wu GB; Xie ZW; Shi DL; Luo M
Front Genet; 2022; 13():942166. PubMed ID: 36246599
[No Abstract] [Full Text] [Related]
12. Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells.
Hong J; Zheng W; Cai X
Comb Chem High Throughput Screen; 2023; 26(7):1364-1374. PubMed ID: 36043792
[TBL] [Abstract][Full Text] [Related]
13. The Natural Compound Dehydrocrenatidine Attenuates Nicotine-Induced Stemness and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma by Regulating a7nAChR-Jak2 Signaling Pathways.
Li CL; Wang CC; Pai HT; Tu SL; Hou PY; Huang CY; Huang MT; Chang YJ
Dis Markers; 2022; 2022():8316335. PubMed ID: 35111269
[TBL] [Abstract][Full Text] [Related]
14. Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways.
Deldar Abad Paskeh M; Mirzaei S; Ashrafizadeh M; Zarrabi A; Sethi G
J Hepatocell Carcinoma; 2021; 8():1415-1444. PubMed ID: 34858888
[TBL] [Abstract][Full Text] [Related]
15. Activation of ERK and p38 Reduces AZD8055-Mediated Inhibition of Protein Synthesis in Hepatocellular Carcinoma HepG2 Cell Line.
Jee HY; Lee YG; Lee S; Elvira R; Seo HE; Lee JY; Han J; Lee K
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769253
[TBL] [Abstract][Full Text] [Related]
16. RanBP3 Regulates Proliferation, Apoptosis and Chemosensitivity of Chronic Myeloid Leukemia Cells
Li Q; Huang Z; Peng Y; Wang X; Jiang G; Wang T; Mou K; Feng W
Front Oncol; 2021; 11():698410. PubMed ID: 34504783
[TBL] [Abstract][Full Text] [Related]
17. Landscape of Prognostic m6A RNA Methylation Regulators in Hepatocellular Carcinoma to Aid Immunotherapy.
Xu Q; Xu H; Deng R; Li N; Mu R; Qi Z; Shen Y; Wang Z; Wen J; Zhao J; Weng D; Huang W
Front Cell Dev Biol; 2021; 9():669145. PubMed ID: 34422799
[No Abstract] [Full Text] [Related]
18. Induced Mitochondrial Alteration and DNA Damage via IFNGR-JAK2-STAT1-PARP1 Pathway Facilitates Viral Hepatitis Associated Hepatocellular Carcinoma Aggressiveness and Stemness.
Cherng YG; Chu YC; Yadav VK; Huang TY; Hsieh MS; Lee KF; Lee WH; Yeh CT; Ong JR
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34199353
[TBL] [Abstract][Full Text] [Related]
19. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma.
Xu Q; Hu Y; Chen S; Zhu Y; Li S; Shen F; Guo Y; Sun T; Chen X; Jiang J; Huang W
Front Mol Biosci; 2021; 8():683240. PubMed ID: 34124163
[No Abstract] [Full Text] [Related]
20. Bioinformatic analysis and
Li W; Kong X; Huang T; Shen L; Wu P; Chen QF
Ann Transl Med; 2020 Nov; 8(21):1422. PubMed ID: 33313167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
